{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:13Z","timestamp":1785416653942,"version":"3.56.0"},"reference-count":121,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Haematologic malignancies have diverse and complex genomic abnormalities, and the correct identification is essential for making the appropriate diagnosis, providing a prognosis, and planning treatment. Improved array comparative genomic hybridisation (array CGH) can provide high-resolution, genome-wide copy number variation detection, and overcomes conventional cytogenetic limitations.\nAim:\u00a0The aim of this study is to determine the role of array CGH in characterising genomic aberrations of haematologic malignancies, focusing on technical advantages, added diagnostic values, and implications for disease reclassification and precision medicine.\nMethods:\u00a0A comprehensive literature search of PubMed, Embase, Web of Science, and Scopus was conducted to identify studies evaluating the diagnostic performance and clinical utility of array CGH in haematologic cancers.\nResults:\u00a0Array CGH detects genomic alterations at kilobase-level resolution and reveals additional abnormalities in approximately 30% of cases with normal results by conventional cytogenetics. It improves molecular subtyping, identifies novel prognostic marker and, when combined with single nucleotide polymorphism arrays, enables detection of uniparental disomy and copy-neutral loss of heterozygosity, thereby enhancing diagnostic yield.\nConclusion:\u00a0Array CGH detects up to 90% of known genomic abnormalities in haematologic malignancies, and its integration with other genomic platforms will considerably enhance diagnostic precision and clinical care for haematopoietic neoplasms.\nWhat this study adds:\u00a0This review emphasises the important role of array CGH\u2019s greater sensitivity to clinically relevant copy number changes compared to routine cytogenetics. Clinical applications of array CGH support precision oncology, especially when combined with single nucleotide polymorphism array or next-generation sequencing technologies.<\/jats:p>","DOI":"10.4102\/ajlm.v15i1.3117","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:52:25Z","timestamp":1784274745000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Array comparative genomic hybridisation in haematological malignancies: A comprehensive review"],"prefix":"10.4102","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8380-0227","authenticated-orcid":false,"given":"Mona Mohammed Hashim","family":"Ellaithi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dvsnx49","id-type":"ROR","asserted-by":"publisher"}],"name":"Al-Neelain University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-2331","authenticated-orcid":false,"given":"Hussam Ali","family":"Osman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00r6fph53","id-type":"ROR","asserted-by":"publisher"}],"name":"Liwa University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Gezici S. 2.19 \u2013 Molecular mechanisms of immune checkpoints as an immunotherapy tool in hematological malignancies. In: Razaei N, editor. Comprehensive hematology and stem cell research [homepage on the Internet]. Amsterdam: Elsevier, 2024 [cited 2025 Jul 28]; p. 366\u2013372. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780443157172000354","DOI":"10.1016\/B978-0-443-15717-2.00035-4"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Strickland GT, El-Kamary SS. 31 \u2013 Viral hepatitis. In: Magill AJ, Hill DR, Solomon T, Ryan ET, editors. Hunter\u2019s tropical medicine and emerging infectious disease [homepage on the Internet]. 9th ed. China: Elsevier; 2013 [cited 2025 Jul 28]. p. 290\u2013305. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B978141604390400031X","DOI":"10.1016\/B978-1-4160-4390-4.00031-X"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kiss S, Gede N, So\u00f3s A, et al. Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis. Crit Rev Oncol Hematol. 2021;168:103504. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103504","DOI":"10.1016\/j.critrevonc.2021.103504"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Dapkevi\u010di\u016bt\u0117 A, \u0160apoka V, Martynova E, Pe\u010deli\u016bnas V. Time from symptom onset to diagnosis and treatment among haematological malignancies: Influencing factors and associated negative outcomes. Medicina (Mex). 2019;55(6):238. https:\/\/doi.org\/10.3390\/medicina55060238","DOI":"10.3390\/medicina55060238"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Zhang N, Wu J, Wang Q, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82. https:\/\/doi.org\/10.1038\/s41408-023-00853-3","DOI":"10.1038\/s41408-023-00853-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"MacDonald WJ, Purcell C, Pinho-Schwermann M, Stubbs NM, Srinivasan PR, El-Deiry WS. Heterogeneity in cancer. Cancers. 2025;17(3):441. https:\/\/doi.org\/10.3390\/cancers17030441","DOI":"10.3390\/cancers17030441"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Federico C, Brancato D, Bruno F, Coniglio E, Sturiale V, Saccone S. Cytogenetics and cytogenomics in clinical diagnostics: Genome architecture, structural variants, and translational applications. Genes. 2025;16(7):780. https:\/\/doi.org\/10.3390\/genes16070780","DOI":"10.3390\/genes16070780"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gonzales PR, Carroll AJ, Korf BR. Overview of clinical cytogenetics. Curr Protoc Hum Genet. 2016;89(1):8.1.1\u20138.1.13. https:\/\/doi.org\/10.1002\/0471142905.hg0801s89","DOI":"10.1002\/0471142905.hg0801s89"},{"key":"ref8","unstructured":"Sinclair A. Genetics 101: Cytogenetics and FISH. Can Med Assoc J. 2002;167(4):373\u2013374."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Bejjani BA, Shaffer LG. Application of array-based comparative genomic hybridization to clinical diagnostics. J Mol Diagn. 2006;8(5):528\u2013533. https:\/\/doi.org\/10.2353\/jmoldx.2006.060029","DOI":"10.2353\/jmoldx.2006.060029"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001;29(3):263\u2013264. https:\/\/doi.org\/10.1038\/ng754","DOI":"10.1038\/ng754"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Peterson JF, Aggarwal N, Smith CA, et al. Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Oncotarget. 2015;6(22):18845\u201318862. https:\/\/doi.org\/10.18632\/oncotarget.4586","DOI":"10.18632\/oncotarget.4586"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Davies JJ, Wilson IM, Lam WL. Array CGH technologies and their applications to cancer genomes. Chromosome Res. 2005;13(3):237\u2013248. https:\/\/doi.org\/10.1007\/s10577-005-2168-x","DOI":"10.1007\/s10577-005-2168-x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Michels E, De Preter K, Van Roy N, Speleman F. Detection of DNA copy number alterations in cancer by array comparative genomic hybridization. Genet Med. 2007;9(9):574\u2013584. https:\/\/doi.org\/10.1097\/GIM.0b013e318145b25b","DOI":"10.1097\/GIM.0b013e318145b25b"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Patel LR, Nykter M, Chen K, Zhang W. Cancer genome sequencing: Understanding malignancy as a disease of the genome, its conformation, and its evolution. Cancer Lett. 2013;340(2):152\u2013160. https:\/\/doi.org\/10.1016\/j.canlet.2012.10.018","DOI":"10.1016\/j.canlet.2012.10.018"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Awuah WA, Shah MH, Sanker V, et al. Advances in chromosomal microarray analysis: Transforming neurology and neurosurgery. Brain Spine. 2025;5:104197. https:\/\/doi.org\/10.1016\/j.bas.2025.104197","DOI":"10.1016\/j.bas.2025.104197"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Lestringant V, Guermouche-Flament H, Jimenez-Pocquet M, Gaillard JB, Penther D. Cytogenetics in the management of hematological malignancies: An overview of alternative technologies for cytogenetic characterization. Curr Res Transl Med. 2024;72(3):103440. https:\/\/doi.org\/10.1016\/j.retram.2024.103440","DOI":"10.1016\/j.retram.2024.103440"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Baldocchi RA, Glynne RJ, Chin K, et al. Design considerations for array CGH to oligonucleotide arrays. Cytometry A. 2005;67A(2):129\u2013136. https:\/\/doi.org\/10.1002\/cyto.a.20161","DOI":"10.1002\/cyto.a.20161"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Manning M, Hudgins L. Use of array-based technology in the practice of medical genetics. Genet Med. 2007;9(9):650\u2013653. https:\/\/doi.org\/10.1097\/GIM.0b013e31814cec3a","DOI":"10.1097\/GIM.0b013e31814cec3a"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Aradhya S, Cherry AM. Array-based comparative genomic hybridization: Clinical contexts for targeted and whole-genome designs. Genet Med. 2007;9(9):553\u2013559. https:\/\/doi.org\/10.1097\/GIM.0b013e318149e354","DOI":"10.1097\/GIM.0b013e318149e354"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yu S, Bittel DC, Kibiryeva N, Zwick DL, Cooley LD. Validation of the Agilent 244K oligonucleotide array\u2013based comparative genomic hybridization platform for clinical cytogenetic diagnosis. Am J Clin Pathol. 2009;132(3):349\u2013360. https:\/\/doi.org\/10.1309\/AJCP1BOUTWF6ERYS","DOI":"10.1309\/AJCP1BOUTWF6ERYS"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Heinrichs S, Li C, Look AT. SNP array analysis in hematologic malignancies: Avoiding false discoveries. Blood. 2010;115(21):4157\u20134161. https:\/\/doi.org\/10.1182\/blood-2009-11-203182","DOI":"10.1182\/blood-2009-11-203182"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Payne AR, Chang SW, Koenig SN, Zinn AR, Garg V. Submicroscopic chromosomal copy number variations identified in children with hypoplastic left heart syndrome. Pediatr Cardiol. 2012;33(5):757\u2013763. https:\/\/doi.org\/10.1007\/s00246-012-0208-9","DOI":"10.1007\/s00246-012-0208-9"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dunbar AJ, Gondek LP, O\u2019Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68(24):10349\u201310357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2754","DOI":"10.1158\/0008-5472.CAN-08-2754"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"O\u2019Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: A novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731\u20132739. https:\/\/doi.org\/10.1182\/blood-2009-10-201848","DOI":"10.1182\/blood-2009-10-201848"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wiszniewska J, Bi W, Shaw C, et al. Combined array CGH plus SNP genome analyses in a single assay for optimized clinical testing. Eur J Hum Genet. 2014;22(1):79\u201387. https:\/\/doi.org\/10.1038\/ejhg.2013.77","DOI":"10.1038\/ejhg.2013.77"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Gondek LP, Tiu R, O\u2019Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS\/MPD, and MDS-derived AML. Blood. 2008;111(3):1534\u20131542. https:\/\/doi.org\/10.1182\/blood-2007-05-092304","DOI":"10.1182\/blood-2007-05-092304"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Makishima H, Maciejewski JP. Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(12):3913\u20133923. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2900","DOI":"10.1158\/1078-0432.CCR-10-2900"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Johnson NA, Hamoudi RA, Ichimura K, et al. Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest. 2006;86(9):968\u2013978. https:\/\/doi.org\/10.1038\/labinvest.3700441","DOI":"10.1038\/labinvest.3700441"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wang K, Li J, Li S, Bolund L, Wiuf C. Estimation of tumor heterogeneity using CGH array data. BMC Bioinformatics. 2009;10(1):12. https:\/\/doi.org\/10.1186\/1471-2105-10-12","DOI":"10.1186\/1471-2105-10-12"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Stricker T, Catenacci DVT, Seiwert TY. Molecular profiling of cancer \u2013 The future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol. 2011;38(2):173\u2013185. https:\/\/doi.org\/10.1053\/j.seminoncol.2011.01.013","DOI":"10.1053\/j.seminoncol.2011.01.013"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs B, G\u00eengu\u021b\u0103 A, Kiss P, et al. Comparing the efficiency of different methods for reliable results in ancient DNA NGS workflow. DNA. 2025;5(2):26. https:\/\/doi.org\/10.3390\/dna5020026","DOI":"10.3390\/dna5020026"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Darai-Ramqvist E, De St\u00e5hl TD, Sandlund A, et al. Array-CGH and multipoint FISH to decode complex chromosomal rearrangements. BMC Genomics. 2006;7(1):330. https:\/\/doi.org\/10.1186\/1471-2164-7-330","DOI":"10.1186\/1471-2164-7-330"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Rabin KR, Man T, Yu A, et al. Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51(2):171\u2013177. https:\/\/doi.org\/10.1002\/pbc.21488","DOI":"10.1002\/pbc.21488"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Coughlin CR, Scharer GH, Shaikh TH. Clinical impact of copy number variation analysis using high-resolution microarray technologies: Advantages, limitations and concerns. Genome Med. 2012;4(10):80. https:\/\/doi.org\/10.1186\/gm381","DOI":"10.1186\/gm381"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Hu L, Yao X, Huang H, et al. Clinical significance of germline copy number variation in susceptibility of human diseases. J Genet Genomics. 2018;45(1):3\u201312. https:\/\/doi.org\/10.1016\/j.jgg.2018.01.001","DOI":"10.1016\/j.jgg.2018.01.001"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hovhannisyan G, Harutyunyan T, Aroutiounian R, Liehr T. DNA copy number variations as markers of mutagenic impact. Int J Mol Sci. 2019;20(19):4723. https:\/\/doi.org\/10.3390\/ijms20194723","DOI":"10.3390\/ijms20194723"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Neveling K, Mantere T, Vermeulen S, et al. Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping. Am J Hum Genet. 2021;108(8):1423\u20131435. https:\/\/doi.org\/10.1016\/j.ajhg.2021.06.001","DOI":"10.1016\/j.ajhg.2021.06.001"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Hujoel MLA, Sherman MA, Barton AR, et al. Influences of rare copy-number variation on human complex traits. Cell. 2022;185(22):4233.e27\u20134248.e27. https:\/\/doi.org\/10.1016\/j.cell.2022.09.028","DOI":"10.1016\/j.cell.2022.09.028"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Oostlander A, Meijer G, Ylstra B. Microarray-based comparative genomic hybridization and its applications in human genetics. Clin Genet. 2004;66(6):488\u2013495. https:\/\/doi.org\/10.1111\/j.1399-0004.2004.00322.x","DOI":"10.1111\/j.1399-0004.2004.00322.x"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Shaffer LG. Microarray-based cytogenetics. In: Gersen SL, Keagle MB, editors. The principles of clinical cytogenetics [homepage on the Internet]. New York, NY: Springer New York, 2013 [cited 2025 Jul 29]; p. 441\u2013450. Available from: https:\/\/link.springer.com\/10.1007\/978-1-4419-1688-4_18","DOI":"10.1007\/978-1-4419-1688-4_18"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Wang L, Rao M, Fang Y, et al. A genome-wide high-resolution array-CGH analysis of cutaneous melanoma and comparison of array-CGH to FISH in diagnostic evaluation. J Mol Diagn. 2013;15(5):581\u2013591. https:\/\/doi.org\/10.1016\/j.jmoldx.2013.04.001","DOI":"10.1016\/j.jmoldx.2013.04.001"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Zakaria Z, Ahid MFM, Ismail A, et al. Chromosomal aberrations in ETV6\/RUNX1-positive childhood Acute lymphoblastic leukemia using 244K oligonucleotide array comparative genomic hybridization. Mol Cytogenet. 2012;5(1):41. https:\/\/doi.org\/10.1186\/1755-8166-5-41","DOI":"10.1186\/1755-8166-5-41"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Ismail A, Ahid F, Moi WN, et al. Genomic landscape of childhood acute lymphoblastic leukemia in Malaysia: Insights from array-CGH. Mol Cytogenet. 2025;18(1):7. https:\/\/doi.org\/10.1186\/s13039-025-00709-4","DOI":"10.1186\/s13039-025-00709-4"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Bokemeyer A, Eckert C, Meyr F, et al. Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6\/RUNX1-positive acute lymphoblastic leukemia. Haematologica. 2014;99(4):706\u2013714. https:\/\/doi.org\/10.3324\/haematol.2012.072470","DOI":"10.3324\/haematol.2012.072470"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Abdelfattah NE, Elsayed GM, Soliman AH, Ebeid EN, El Ashry MS. Copy number alterations in pediatric B-cell precursor acute lymphoblastic leukemia patients and their association with patients\u2019 outcome. Ann Hematol. 2025;104(3):1821\u20131832. https:\/\/doi.org\/10.1007\/s00277-024-06102-2","DOI":"10.1007\/s00277-024-06102-2"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Robledo C, Garc\u00eda JL, Caballero D, et al. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer. 2009;115(16):3728\u20133737. https:\/\/doi.org\/10.1002\/cncr.24430","DOI":"10.1002\/cncr.24430"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Dawson AJ, Yanofsky R, Vallente R, et al. Array comparative genomic hybridization and cytogenetic analysis in pediatric acute leukemias. Curr Oncol. 2011;18(5):210\u2013217. https:\/\/doi.org\/10.3747\/co.v18i5.770","DOI":"10.3747\/co.v18i5.770"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Koh KN, Lee JO, Seo EJ, et al. Clinical significance of previously cryptic copy number alterations and loss of heterozygosity in pediatric acute myeloid leukemia and myelodysplastic syndrome determined using combined array comparative genomic hybridization plus single-nucleotide polymorphism microarray analyses. J Korean Med Sci. 2014;29(7):926\u2013933. https:\/\/doi.org\/10.3346\/jkms.2014.29.7.926","DOI":"10.3346\/jkms.2014.29.7.926"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Merup M, Jansson M, Corcoran M, et al. A FISH cosmid \u2018cocktail\u2019 for detection of 13q deletions in chronic lymphocytic leukaemia \u2013 Comparison with cytogenetics and Southern hybridization. Leukemia. 1998;12(5):705\u2013709. https:\/\/doi.org\/10.1038\/sj.leu.2400920","DOI":"10.1038\/sj.leu.2400920"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Grygalewicz B, Woroniecka R, Rygier J, et al. Monoallelic and biallelic deletions of 13q14 in a group of CLL\/SLL patients investigated by CGH haematological cancer and SNP array (8x60K). Mol Cytogenet. 2016;9(1):1. https:\/\/doi.org\/10.1186\/s13039-015-0212-x","DOI":"10.1186\/s13039-015-0212-x"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Y\u0131lmaz M, Dilhan Kuru R, Erdo\u011fan I, Soysal T, Hac\u0131hanefioglu S, Baykara O. Investigation of 13q14.3 deletion by cytogenetic analysis and FISH technique and miRNA-15a and miRNA-16-1 by real time PCR in chronic lymphocytic leukemia. Afr Health Sci. 2022;22(3):173\u2013182. https:\/\/doi.org\/10.4314\/ahs.v22i3.20","DOI":"10.4314\/ahs.v22i3.20"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Gunn SR, Mohammed MS, Gorre ME, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn. 2008;10(5):442\u2013451. https:\/\/doi.org\/10.2353\/jmoldx.2008.080033","DOI":"10.2353\/jmoldx.2008.080033"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017;92(12):1393\u20131397. https:\/\/doi.org\/10.1002\/ajh.24808","DOI":"10.1002\/ajh.24808"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"McCafferty N, Stewart JP, Darzentas N, et al. A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements. Haematologica. 2022;108(5):1313\u20131321. https:\/\/doi.org\/10.3324\/haematol.2022.281928","DOI":"10.3324\/haematol.2022.281928"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Chen W, Houldsworth J, Olshen AB, et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood. 2006;107(6):2477\u20132485. https:\/\/doi.org\/10.1182\/blood-2005-07-2950","DOI":"10.1182\/blood-2005-07-2950"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Lossos IS. Diffuse large B cell lymphoma: From gene expression profiling to prediction of outcome. Biol Blood Marrow Transplant. 2008;14(1):108\u2013111. https:\/\/doi.org\/10.1016\/j.bbmt.2007.10.020","DOI":"10.1016\/j.bbmt.2007.10.020"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Liu W, Xie CC, Zhu Y, et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008;10(8):897\u2013907, IN23\u2013IN37. https:\/\/doi.org\/10.1593\/neo.08428","DOI":"10.1593\/neo.08428"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Lode L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95(11):1973\u20131976. https:\/\/doi.org\/10.3324\/haematol.2010.023697","DOI":"10.3324\/haematol.2010.023697"},{"key":"ref59","unstructured":"Padala SA, Kallam A. Diffuse large B-cell lymphoma. In: StatPearls [homepage on the Internet]. Treasure Island, FL: StatPearls Publishing; 2025 [cited 2025 Jul 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557796\/"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Lindsley RC, Ebert BL. The biology and clinical impact of genetic lesions in myeloid malignancies. Blood. 2013;122(23):3741\u20133748. https:\/\/doi.org\/10.1182\/blood-2013-06-460295","DOI":"10.1182\/blood-2013-06-460295"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Gronseth CM, McElhone SE, Storer BE, et al. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer. 2015;121(17):2900\u20132908. https:\/\/doi.org\/10.1002\/cncr.29475","DOI":"10.1002\/cncr.29475"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Yeung CCS, McElhone S, Chen XY, et al. Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol. 2018;31(4):569\u2013580. https:\/\/doi.org\/10.1038\/modpathol.2017.157","DOI":"10.1038\/modpathol.2017.157"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Biswas S, Achrekar AR, Ugale PR, et al. Validation of the 2022 European leukemianet risk stratification of acute myeloid leukemia (AML). Blood. 2024;144(Supplement 1):4310. https:\/\/doi.org\/10.1182\/blood-2024-199045","DOI":"10.1182\/blood-2024-199045"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Mustapha MT, Ozsahin DU. Morphological analysis and subtype detection of acute myeloid leukemia in high-resolution blood smears using ConvNeXT. AI. 2025;6(3):45. https:\/\/doi.org\/10.3390\/ai6030045","DOI":"10.3390\/ai6030045"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Greisman HA, Hoffman NG, Yi HS. Rapid high-resolution mapping of balanced chromosomal rearrangements on tiling CGH arrays. J Mol Diagn. 2011;13(6):621\u2013633. https:\/\/doi.org\/10.1016\/j.jmoldx.2011.07.005","DOI":"10.1016\/j.jmoldx.2011.07.005"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Zhang C, Cerveira E, Romanovitch M, Zhu Q. Array-based comparative genomic hybridization (aCGH). In: Wan TSK, editor. Cancer cytogenetics [homepage on the Internet]. Methods in Molecular Biology; vol. 1541. New York, NY: Springer New York, 2017 [cited 2025 Jul 30]; p. 167\u2013179. Available from: http:\/\/link.springer.com\/10.1007\/978-1-4939-6703-2_15","DOI":"10.1007\/978-1-4939-6703-2_15"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Wa CV, De Vries S, Chen YY, Waldman FM, Hwang ES. Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. Mod Pathol. 2005;18(4):591\u2013597. https:\/\/doi.org\/10.1038\/modpathol.3800332","DOI":"10.1038\/modpathol.3800332"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Gunn SR, Robetorye RS, Mohammed MS. Comparative genomic hybridization arrays in clinical pathology: Progress and challenges. Mol Diagn Ther. 2007;11(2):73\u201377. https:\/\/doi.org\/10.1007\/BF03256225","DOI":"10.1007\/BF03256225"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258\u20131266. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1429","DOI":"10.1158\/1078-0432.CCR-14-1429"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Lahoz S, Archilla I, Asensio E, et al. Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage II colon cancer. J Pathol. 2022;257(1):68\u201381. https:\/\/doi.org\/10.1002\/path.5870","DOI":"10.1002\/path.5870"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Tilly H, Gomes Da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v116\u2013v125. https:\/\/doi.org\/10.1093\/annonc\/mdv304","DOI":"10.1093\/annonc\/mdv304"},{"key":"ref72","unstructured":"Xue Y, Wang Q, He X. Clear cell variant of diffuse large B-cell lymphoma: A case report and review of the literature. Int J Clin Exp Pathol. 2015;8(6):7594\u20137599."},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Sethi A, Tandon A, Mishra H, Singh I. Diffuse large B-cell lymphoma: An immunohistochemical approach to diagnosis. J Oral Maxillofac Pathol. 2019;23(2):284\u2013288. https:\/\/doi.org\/10.4103\/jomfp.JOMFP_294_18","DOI":"10.4103\/jomfp.JOMFP_294_18"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"McCabe MG, Ichimura K, Liu L, et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol. 2006;65(6):549\u2013561. https:\/\/doi.org\/10.1097\/00005072-200606000-00003","DOI":"10.1097\/00005072-200606000-00003"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Bailey NG, Gross T, Lim MS. Chapter 20 \u2013 Genomic basis of pediatric lymphomas. In: Dellaire G, Berman JM, Arceci RJ, editors. Cancer genomics \u2013 From bench to personalized medicine [homepage on the internet]. London: Elsevier, 2014 [cited 2025 Jul 30]; p. 341\u2013355. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780123969675000207","DOI":"10.1016\/B978-0-12-396967-5.00020-7"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): A review. Hematol Oncol. 2008;26(1):8\u201320. https:\/\/doi.org\/10.1002\/hon.836","DOI":"10.1002\/hon.836"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2009;15(1):30\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1808","DOI":"10.1158\/1078-0432.CCR-08-1808"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 2008;112(8):3412\u20133424. https:\/\/doi.org\/10.1182\/blood-2007-11-122028","DOI":"10.1182\/blood-2007-11-122028"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Tefferi A, Sirhan S, Sun Y, et al. Oligonucleotide array CGH studies in myeloproliferative neoplasms: Comparison with JAK2V617F mutational status and conventional chromosome analysis. Leuk Res. 2009;33(5):662\u2013664. https:\/\/doi.org\/10.1016\/j.leukres.2008.09.009","DOI":"10.1016\/j.leukres.2008.09.009"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Reiter A, Invernizzi R, Cross NCP, Cazzola M. Molecular basis of myelodysplastic\/myeloproliferative neoplasms. Haematologica. 2009;94(12):1634\u20131638. https:\/\/doi.org\/10.3324\/haematol.2009.014001","DOI":"10.3324\/haematol.2009.014001"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Ernst T, Chase A, Zoi K, et al. Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms. Haematologica. 2010;95(9):1473\u20131480. https:\/\/doi.org\/10.3324\/haematol.2010.021808","DOI":"10.3324\/haematol.2010.021808"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Evans AG, Ahmad A, Burack WR, Iqbal MA. Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance. Mod Pathol. 2016;29(10):1183\u20131199. https:\/\/doi.org\/10.1038\/modpathol.2016.104","DOI":"10.1038\/modpathol.2016.104"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6(2):e393. https:\/\/doi.org\/10.1038\/bcj.2016.5","DOI":"10.1038\/bcj.2016.5"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Patel BJ, Przychodzen B, Thota S, et al. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017;31(12):2815\u20132823. https:\/\/doi.org\/10.1038\/leu.2017.164","DOI":"10.1038\/leu.2017.164"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Palomo L, Acha P, Sol\u00e9 F. Genetic aspects of myelodysplastic\/myeloproliferative neoplasms. Cancers. 2021;13(9):2120. https:\/\/doi.org\/10.3390\/cancers13092120","DOI":"10.3390\/cancers13092120"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Gelsi-Boyer V, Trouplin V, Ad\u00e9la\u00efde J, et al. Genome profiling of chronic myelomonocytic leukemia: Frequent alterations of RAS and RUNX1genes. BMC Cancer. 2008;8(1):299. https:\/\/doi.org\/10.1186\/1471-2407-8-299","DOI":"10.1186\/1471-2407-8-299"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Kamalakaran S, Varadan V, Janevski A, et al. Translating next generation sequencing to practice: Opportunities and necessary steps. Mol Oncol. 2013;7(4):743\u2013755. https:\/\/doi.org\/10.1016\/j.molonc.2013.04.008","DOI":"10.1016\/j.molonc.2013.04.008"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell. 2013;155(1):27\u201338. https:\/\/doi.org\/10.1016\/j.cell.2013.09.006","DOI":"10.1016\/j.cell.2013.09.006"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Tattini L, D\u2019Aurizio R, Magi A. Detection of genomic structural variants from next-generation sequencing data. Front Bioeng Biotechnol. 2015;3:92. https:\/\/doi.org\/10.3389\/fbioe.2015.00092","DOI":"10.3389\/fbioe.2015.00092"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Chakravarty D, Solit DB. Clinical cancer genomic profiling. Nat Rev Genet. 2021;22(8):483\u2013501. https:\/\/doi.org\/10.1038\/s41576-021-00338-8","DOI":"10.1038\/s41576-021-00338-8"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Liu N, Guan M, Ma B, et al. Unraveling genetic mysteries: A comprehensive review of GWAS and DNA insights in animal and plant pathosystems. Int J Biol Macromol. 2025;285:138216. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138216","DOI":"10.1016\/j.ijbiomac.2024.138216"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Makhoba XH, Viegas C, Mosa RA, Viegas FPD, Pooe OJ. Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Des Devel Ther. 2020;14:3235\u20133249. https:\/\/doi.org\/10.2147\/DDDT.S257494","DOI":"10.2147\/DDDT.S257494"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Ruiz C, Zitnik M, Leskovec J. Identification of disease treatment mechanisms through the multiscale interactome. Nat Commun. 2021;12(1):1796. https:\/\/doi.org\/10.1038\/s41467-021-21770-8","DOI":"10.1038\/s41467-021-21770-8"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Tihagam RD, Bhatnagar S. A multi-platform normalization method for meta-analysis of gene expression data. Methods. 2023;217:43\u201348. https:\/\/doi.org\/10.1016\/j.ymeth.2023.06.012","DOI":"10.1016\/j.ymeth.2023.06.012"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Janyasupab P, Suratanee A, Plaimas K. GeneCompete: An integrative tool of a novel union algorithm with various ranking techniques for multiple gene expression data. PeerJ Comput Sci. 2023;9:e1686. https:\/\/doi.org\/10.7717\/peerj-cs.1686","DOI":"10.7717\/peerj-cs.1686"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Tan DSP, Lambros MBK, Natrajan R, Reis-Filho JS. Getting it right: Designing microarray (and not \u2018microawry\u2019) comparative genomic hybridization studies for cancer research. Lab Invest. 2007;87(8):737\u2013754. https:\/\/doi.org\/10.1038\/labinvest.3700593","DOI":"10.1038\/labinvest.3700593"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Czy\u017c ZT, Hoffmann M, Schlimok G, Polzer B, Klein CA. Reliable single cell array CGH for clinical samples. PLoS One. 2014;9(1):e85907. https:\/\/doi.org\/10.1371\/journal.pone.0085907","DOI":"10.1371\/journal.pone.0085907"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Cai Z, Poulos RC, Liu J, Zhong Q. Machine learning for multi-omics data integration in cancer. iScience. 2022;25(2):103798. https:\/\/doi.org\/10.1016\/j.isci.2022.103798","DOI":"10.1016\/j.isci.2022.103798"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Mao Y, Shangguan D, Huang Q, et al. Emerging artificial intelligence-driven precision therapies in tumor drug resistance: Recent advances, opportunities, and challenges. Mol Cancer. 2025;24(1):123. https:\/\/doi.org\/10.1186\/s12943-025-02321-x","DOI":"10.1186\/s12943-025-02321-x"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Srivastava R. Advancing precision oncology with AI-powered genomic analysis. Front Pharmacol. 2025;16:1591696. https:\/\/doi.org\/10.3389\/fphar.2025.1591696","DOI":"10.3389\/fphar.2025.1591696"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Sagoo GS, Mohammed S, Barton G, et al. Cost effectiveness of using array-CGH for diagnosing learning disability. Appl Health Econ Health Policy. 2015;13(4):421\u2013432. https:\/\/doi.org\/10.1007\/s40258-015-0172-7","DOI":"10.1007\/s40258-015-0172-7"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Miller DT, Adam MP, Aradhya S, et al. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749\u2013764. https:\/\/doi.org\/10.1016\/j.ajhg.2010.04.006","DOI":"10.1016\/j.ajhg.2010.04.006"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Ostrovnaya I, Begg CB. Testing clonal relatedness of tumors using array comparative genomic hybridization: A statistical challenge. Clin Cancer Res. 2010;16(5):1358\u20131367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2398","DOI":"10.1158\/1078-0432.CCR-09-2398"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Rubio C, Rodrigo L, Mir P, et al. Use of array comparative genomic hybridization (array-CGH) for embryo assessment: Clinical results. Fertil Steril. 2013;99(4):1044\u20131048. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.01.094","DOI":"10.1016\/j.fertnstert.2013.01.094"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Higgins RA, Gunn SR, Robetorye RS. Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. Mol Diagn Ther. 2008;12(5):271\u2013280. https:\/\/doi.org\/10.1007\/BF03256292","DOI":"10.1007\/BF03256292"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Patel A, Kang S, Lennon PA, et al. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am J Hematol. 2008;83(7):540\u2013546. https:\/\/doi.org\/10.1002\/ajh.21145","DOI":"10.1002\/ajh.21145"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Laplane L. 3083 \u2013 Clonal evolution: A philosophy of science analysis. Exp Hematol. 2021;100:S82. https:\/\/doi.org\/10.1016\/j.exphem.2021.12.301","DOI":"10.1016\/j.exphem.2021.12.301"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Sandmann S, Behrens YL, Davenport C, et al. Clonal evolution at first sight: A combined visualization of diverse diagnostic methods improves understanding of leukemic progression. Front Oncol. 2022;12:888114. https:\/\/doi.org\/10.3389\/fonc.2022.888114","DOI":"10.3389\/fonc.2022.888114"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Veeraraghavan J, Ma J, Hu Y, Wang XS. Recurrent and pathological gene fusions in breast cancer: Current advances in genomic discovery and clinical implications. Breast Cancer Res Treat. 2016;158(2):219\u2013232. https:\/\/doi.org\/10.1007\/s10549-016-3876-y","DOI":"10.1007\/s10549-016-3876-y"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Al-Anazi WK, Dridi W, Al-Anazi KA. Cytogenetics, molecular genetics and epigenetics and their impact on the management of acute lymphoblastic leukemia. J Mol Genet Med. 2017;11:4. https:\/\/doi.org\/10.4172\/1747-0862.1000308","DOI":"10.4172\/1747-0862.1000308"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Schmidt K, Carroll JS, Yee E, et al. The lncRNA SLNCR recruits the androgen receptor to EGR1-bound genes in melanoma and inhibits expression of tumor suppressor p21. Cell Rep. 2019;27(8):2493.e4\u20132507.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.101","DOI":"10.1016\/j.celrep.2019.04.101"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Powers MP. The ever-changing world of gene fusions in cancer: A secondary gene fusion and progression. Oncogene. 2019;38(47):7197\u20137199. https:\/\/doi.org\/10.1038\/s41388-019-1057-2","DOI":"10.1038\/s41388-019-1057-2"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Akkari Y, Baughn LB, Kim A, et al. Section E6.1\u20136.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes. Genet Med. 2024;26(4):101054. https:\/\/doi.org\/10.1016\/j.gim.2023.101054","DOI":"10.1016\/j.gim.2023.101054"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Horsley SW, Mackay A, Iravani M, et al. Array CGH of fusion gene\u2013positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss. Genes Chromosomes Cancer. 2006;45(6):554\u2013564. https:\/\/doi.org\/10.1002\/gcc.20317","DOI":"10.1002\/gcc.20317"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Jamalinia M, Weiskirchen R. Advances in personalized medicine: Translating genomic insights into targeted therapies for cancer treatment. Ann Transl Med. 2025;13(2):18. https:\/\/doi.org\/10.21037\/atm-25-34","DOI":"10.21037\/atm-25-34"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Nowak NJ, Miecznikowski J, Moore SR, et al. Challenges in array comparative genomic hybridization for the analysis of cancer samples. Genet Med. 2007;9(9):585\u2013595. https:\/\/doi.org\/10.1097\/GIM.0b013e3181461c4a","DOI":"10.1097\/GIM.0b013e3181461c4a"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Tirado CA, Chen W, Garc\u00eda R, Kohlman KA, Rao N. Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large b-cell lymphoma: A review of the literature. J Hematol Oncol. 2012;5(1):54. https:\/\/doi.org\/10.1186\/1756-8722-5-54","DOI":"10.1186\/1756-8722-5-54"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Wills QF, Mead AJ. Application of single-cell genomics in cancer: Promise and challenges. Hum Mol Genet. 2015;24(R1):R74\u2013R84. https:\/\/doi.org\/10.1093\/hmg\/ddv235","DOI":"10.1093\/hmg\/ddv235"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Kashyap A, Rapsomaniki MA, Barros V, et al. Quantification of tumor heterogeneity: From data acquisition to metric generation. Trends Biotechnol. 2022;40(6):647\u2013676. https:\/\/doi.org\/10.1016\/j.tibtech.2021.11.006","DOI":"10.1016\/j.tibtech.2021.11.006"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Rack KA, Van Den Berg E, Haferlach C, et al. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia. 2019;33(8):1851\u20131867. https:\/\/doi.org\/10.1038\/s41375-019-0378-z","DOI":"10.1038\/s41375-019-0378-z"}],"container-title":["African Journal of Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/3117\/3537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:53:30Z","timestamp":1784274810000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/3117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/ajlm.v15i1.3117","relation":{},"ISSN":["2225-2002","2225-2010"],"issn-type":[{"value":"2225-2002","type":"print"},{"value":"2225-2010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"a3117"}}